Literature DB >> 12517980

Diverse repertoire of HIV-1 p24-specific, IFN-gamma-producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy.

Eli Boritz1, Brent E Palmer, Brian Livingston, Alessandro Sette, Cara C Wilson.   

Abstract

HIV-1 Ag-specific CD4(+) T cell proliferative responses in human subjects with advanced, untreated HIV-1 disease are often weak or undetectable. Conversely, HIV-1-specific CD4(+) T cell proliferation is occasionally detected following suppression of HIV-1 replication with highly active antiretroviral therapy (HAART). These observations suggest that unchecked HIV-1 replication may lead to depletion or dysfunction of HIV-1-specific CD4(+) T cells, and that these defects may be partially corrected by viral suppression and subsequent immune reconstitution. However, the impact of this immune reconstitution on the repertoire of HIV-1-specific CD4(+) T cells has not been thoroughly evaluated. To examine the HIV-1-specific CD4(+) T cell repertoire in this clinical setting, we established HIV-1 p24-specific CD4(+) T cell clones from a successfully HAART-treated subject whose pretreatment peripheral CD4 count was 0 cells/ micro l. Eleven different p24-specific CD4(+) T cell clonotypes were distinguished among 13 clones obtained. Most clones produced both IFN-gamma and IL-4 upon Ag stimulation. Clones targeted eight distinct epitopes that varied in their conservancy among HIV-1 strains, and responses were restricted by one of three MHC II molecules. Clones showed a range of functional avidities for both protein and peptide Ags. Additional studies confirmed that multiple HIV-1 p24-derived epitopes were targeted by IFN-gamma-producing CD4(+) cells from subjects first treated with HAART during advanced HIV-1 disease (median, 4.5 peptides/subject; range, 3-6). These results suggest that in HAART-treated subjects whose peripheral CD4(+) T cell pools were once severely depleted, the HIV-1-specific CD4(+) T cell repertoire may include a diverse array of clonotypes targeting multiple HIV-1 epitopes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517980     DOI: 10.4049/jimmunol.170.2.1106

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

2.  A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition.

Authors:  Zarixia Zavala-Ruiz; Iwona Strug; Bruce D Walker; Philip J Norris; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-26       Impact factor: 11.205

3.  Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels.

Authors:  Eli Boritz; Brent E Palmer; Cara C Wilson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity.

Authors:  Benoît Vingert; Santiago Perez-Patrigeon; Patricia Jeannin; Olivier Lambotte; Faroudy Boufassa; Fabrice Lemaître; William W Kwok; Ioannis Theodorou; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

6.  Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.

Authors:  Cara C Wilson; Mark J Newman; Brian D Livingston; Samantha MaWhinney; Jeri E Forster; Jim Scott; Robert T Schooley; Constance A Benson
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

7.  Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection.

Authors:  J Mauricio Calvo-Calle; Iwona Strug; Maria-Dorothea Nastke; Stephen P Baker; Lawrence J Stern
Journal:  PLoS Pathog       Date:  2007-10-12       Impact factor: 6.823

8.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays.

Authors:  Sune Justesen; Mikkel Harndahl; Kasper Lamberth; Lise-Lotte B Nielsen; Søren Buus
Journal:  Immunome Res       Date:  2009-05-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.